Celularity Inc
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Emerging growth company
State of Incorporation
DE
Business Address
170 PARK AVE, FLORHAM PARK, NJ, 07932
Mailing Address
170 PARK AVE, FLORHAM PARK, NJ, 07932
Phone
(908) 768-2170
Fiscal Year End
1231
EIN
831702591
Financial Overview
FY2024
$123.84M
Total Liabilities
$198.90M
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 10, 2026 | View on SEC |
| 8-K Current report of material events | March 5, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 11, 2026 | View on SEC |
| 8-K Current report of material events | January 21, 2026 | View on SEC |
| 4/A Insider transaction amendment | January 15, 2026 | View on SEC |
| 4/A Insider transaction amendment | January 15, 2026 | View on SEC |
| 4/A Insider transaction amendment | January 15, 2026 | View on SEC |
| 4/A Insider transaction amendment | January 15, 2026 | View on SEC |
| 4 Insider stock transaction report | January 14, 2026 | View on SEC |
| 4 Insider stock transaction report | January 14, 2026 | View on SEC |
Material Events
8-K
Legal Issue
December 5, 2025
Medium Impact
- Celularity Inc. received a warning letter from the U.S. Food and Drug Administration (FDA) regarding the marketing of its product Interfyl.
- The FDA stated that Celularity's marketing materials for Interfyl included 'outcome-based claims' and mentioned 'metabolic activity within the body' that go beyond its current regulatory designation.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.